What We're Reading: Page 108
Industry reads hand-picked by our editors
Oct 19, 2022
-
CNBC
FDA authorizes Novavax’s Covid shots as mix-and-match booster to Pfizer or Moderna
-
Bloomberg Law
Better Antibiotic Trials Sought as Congress Weighs Funding Bill
-
Endpoints News
FDA commissioner on accelerated approval reforms: ‘Need to address as soon as possible’
-
Wired
How Iodine Pills Can—and Can’t—Help Against Radiation
Oct 18, 2022
Oct 17, 2022
-
Associated Press
Biden pushing lower prescription drug costs in midterm press
-
FiercePharma
Novartis dealt another blow in ongoing Gilenya patent feud
-
MarketWatch
Milestone Pharmaceuticals Sees Positive Results in Etripamil Trial
-
Reuters
Bill & Melinda Gates Foundation pledge $1.2 billion to eradicate polio
Oct 14, 2022
Oct 13, 2022
-
The New York Times
After Giving Up on Cancer Vaccines, Doctors Start to Find Hope
-
Business Insider
CRISPR Gene-Editing Biotechs Keep Growing Despite Downturn
-
Financial Times
Beijing’s failure to import mRNA Covid jabs ‘mind-boggling,’ says BeiGene executive
Oct 12, 2022
Oct 11, 2022
-
The Washington Post
For decades, fear and failure in the hunt for an RSV vaccine. Now, success.
-
The Wall Street Journal
Bio-Rad Laboratories in Talks to Combine With Qiagen
-
Reuters
U.S. finds new quality problems at Lilly drug factory
-
Stat News
For tiny biotech, Alzheimer’s drug means vindication and a fortune
Previous
